Miguel Negrin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5781540/publications.pdf

Version: 2024-02-01

623734 501196 39 864 14 28 citations g-index h-index papers 50 50 50 889 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Effectiveness of CPAP vs. Noninvasive Ventilation Based on Disease Severity in Obesity Hypoventilation Syndrome and Concomitant Severe Obstructive Sleep Apnea. Archivos De Bronconeumologia, 2022, 58, 228-236.	0.8	5
2	Bayesian Meta-Analysis for Binary Data and Prior Distribution on Models. International Journal of Environmental Research and Public Health, 2021, 18, 809.	2.6	4
3	Non-Parametric Generalized Additive Models as a Tool for Evaluating Policy Interventions. Mathematics, 2021, 9, 299.	2.2	2
4	Telemedicine Strategy for CPAP Titration and Early Follow-up for Sleep Apnea During COVID-19 and Post-Pandemic Future. Archivos De Bronconeumologia, 2021, 57, 56-58.	0.8	10
5	Telemedicine Strategy to Rescue CPAP Therapy in Sleep Apnea Patients with Low Treatment Adherence: A Pilot Study. Journal of Clinical Medicine, 2021, 10, 4123.	2.4	4
6	Echocardiographic Changes with Positive Airway Pressure Therapy in Obesity Hypoventilation Syndrome. Long-Term Pickwick Randomized Controlled Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 586-597.	5.6	34
7	Meta-Analysis with Few Studies and Binary Data: A Bayesian Model Averaging Approach. Mathematics, 2020, 8, 2159.	2.2	2
8	Cost-effectiveness of positive airway pressure modalities in obesity hypoventilation syndrome with severe obstructive sleep apnoea. Thorax, 2020, 75, 459-467.	5.6	18
9	Impact of the Spanish smoke-free laws on cigarette sales, 2000–2015: partial bans on smoking in public places failed and only a total tobacco ban worked. Health Economics, Policy and Law, 2019, 14, 536-552.	1.8	11
10	Impact of the implementation of a Fracture Liaison Service on pharmaceutical expenses for osteoporosis compared to an area without an FLS. Expert Review of Pharmacoeconomics and Outcomes Research, 2019, 19, 81-87.	1.4	2
11	Comprehensive management of obstructive sleep apnea by telemedicine: Clinical improvement and cost-effectiveness of a Virtual Sleep Unit. A randomized controlled trial. PLoS ONE, 2019, 14, e0224069.	2.5	38
12	Long-term clinical effectiveness of continuous positive airway pressure therapy versus non-invasive ventilation therapy in patients with obesity hypoventilation syndrome: a multicentre, open-label, randomised controlled trial. Lancet, The, 2019, 393, 1721-1732.	13.7	126
13	Bayesian meta-analysis: The role of the between-sample heterogeneity. Statistical Methods in Medical Research, 2018, 27, 3643-3657.	1.5	31
14	Bayesian Solutions for Handling Uncertainty in Survival Extrapolation. Medical Decision Making, 2017, 37, 367-376.	2.4	16
15	Modelling time-varying asymmetric information component of transaction costs. Revista Espanola De Financiacion Y Contabilidad, 2016, 45, 440-465.	0.7	2
16	Bayesian Approach to Evidence Synthesis. , 2016, , 155-160.		0
17	A Bayesian cost-effectiveness analysis of a telemedicine-based strategy for the management of sleep apnoea: a multicentre randomised controlled trial. Thorax, 2015, 70, 1054-1061.	5.6	103
18	A Bayesian sensitivity study of risk difference in the meta-analysis of binary outcomes from sparse data. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 317-322.	1.4	4

#	Article	IF	CITATIONS
19	Time trends in socio-economic inequalities in the lack of access to dental services among children in Spain 1987-2011. International Journal for Equity in Health, 2015, 14, 9.	3.5	11
20	Objective Bayesian metaâ€analysis for sparse discrete data. Statistics in Medicine, 2014, 33, 3676-3692.	1.6	15
21	BAYESIAN ASYMMETRIC LOGIT MODEL FOR DETECTING RISK FACTORS IN MOTOR RATEMAKING. ASTIN Bulletin, 2014, 44, 445-457.	1.0	6
22	Equity in specialist waiting times by socioeconomic groups: evidence from Spain. European Journal of Health Economics, 2014, 15, 323-334.	2.8	24
23	Utilisation and Waiting Times: Two Inseparable Aspects of the Analysis of Equity. Hacienda Publica Espanola, 2014, 208, 11-38.	0.2	4
24	Optimal treatments in cost-effectiveness analysis in the presence of covariates: Improving patient subgroup definition. European Journal of Operational Research, 2013, 226, 173-182.	5.7	3
25	Effectiveness of Three Sleep Apnea Management Alternatives. Sleep, 2013, 36, 1799-1807.	1.1	29
26	Optimal healthcare decisions: The importance of the covariates in cost–effectiveness analysis. European Journal of Operational Research, 2012, 218, 512-522.	5.7	12
27	Comparing meta-analyses for chronic obstructive pulmonary disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 277-279.	1.4	2
28	Effectiveness of home respiratory polygraphy for the diagnosis of sleep apnoea and hypopnoea syndrome. Thorax, 2011, 66, 567-573.	5.6	139
29	Complementing information from incremental net benefit: a Bayesian perspective. Health Services and Outcomes Research Methodology, 2010, 10, 86-99.	1.8	4
30	Optimal healthcare decisions: Comparing medical treatments on a cost-effectiveness basis. European Journal of Operational Research, 2010, 204, 180-187.	5.7	13
31	Bayesian Analysis of Nosocomial Infection Risk and Length of Stay in a Department of General and Digestive Surgery. Value in Health, 2010, 13, 431-439.	0.3	25
32	Bayesian Variable Selection in Cost-Effectiveness Analysis. International Journal of Environmental Research and Public Health, 2010, 7, 1577-1596.	2.6	2
33	A Bayesian Net Benefit Approach to Costâ€effectiveness Analysis in Health Technology Assessment. International Journal of the Economics of Business, 2009, 16, 323-345.	1.7	3
34	Incorporating model uncertainty in cost-effectiveness analysis: A Bayesian model averaging approach. Journal of Health Economics, 2008, 27, 1250-1259.	2.7	18
35	Methodological Aspects in the Assessment of Treatment Effects in Observational Health Outcomes Studies. Applied Health Economics and Health Policy, 2006, 5, 11-25.	2.1	41
36	Bayesian cost-effectiveness analysis with two measures of effectiveness: the cost-effectiveness acceptability plane. Health Economics (United Kingdom), 2006, 15, 363-372.	1.7	17

MIGUEL NEGRIN

#	Article	IF	CITATIONS
37	Using covariates to reduce uncertainty in the economic evaluation of clinical trial data. Health Economics (United Kingdom), 2005, 14, 545-557.	1.7	15
38	Bayesian regression models for cost-effectiveness analysis. European Journal of Health Economics, 2005, 6, 45-52.	2.8	12
39	Self-perceived health status of schizophrenic patients in Spain: analysis of geographic differences. Expert Review of Pharmacoeconomics and Outcomes Research, 2005, 5, 531-540.	1.4	4